How biotech and pharma firms can license IP from federal programs

8 December 2022

This week, patent attorney Jane Dai, from IP specialist Knobbe Martens, provides an Expert View on considerations for biotech and pharma firms when making use of intellectual property from federally-funded programs.

Earlier this month, US President Joe Biden told a Carlsbad, California audience that America’s future rests on major breakthroughs in technology and science. “Other countries are closing in fast,” he elaborated. “The CHIPS and Science Act sets us on a path to move up again.”

The president was referring to a law he signed in August, the Creating Helpful Incentives to Produce Semiconductors and Science Act of 2022 (CHIPS Act).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber



Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight

More Features in Biotechnology